On-Farm Multiplication Now Has a Statute, and It Competes With the Product It Copies

On 23 December 2024 Brazil sanctioned Lei nº 15.070 with no vetoes. The law regulates bioinsumo classification and treatment, ratifies the National Bioinsumos Programme, and — the part that matters commercially — gives on-farm biological production a legal identity.

That single provision is the most consequential thing to happen to the biologicals market in a decade, and it cuts in both directions at once. Legal certainty accelerates adoption. It also hands the cheapest possible competitor to a purchased inoculant a statute of its own.

What the law actually does

Three things. It defines bioinsumos as a regulated category rather than an unclassified agricultural input, so a product can now be described, registered and sold with a legal description attached. It sets out treatment requirements. And it legitimises the multiplication of biological organisms on the farm that will use them — previously a grey area that varied by state, inspector and crop.

For a grower, the third provision removes a compliance risk that had nothing to do with agronomy. For a supplier, it removes an ambiguity that was quietly protecting the addressable market.

Why the economics are so one-sided

Inoculants are the most adopted biological product in Brazil and the least remunerative per hectare. They sit on 40 per cent of all treated area and generate 13 per cent of the value. The revenue intensity is R$ 10.4 per treated hectare against R$ 54.1 for biofungicides.

A rhizobial inoculant is a commodity organism applied at a few litres per hectare. The value it creates accrues to the grower as avoided nitrogen fertiliser, not to the supplier as price. There is no proprietary trait inside the seed, no resistance-management story to renew each season, and no way to differentiate on performance when the performance is nitrogen fixation and everyone’s product fixes nitrogen.

Now add a statute that says multiplying that organism on your own farm is a regulated, permitted activity. The barrier to on-farm production was never capital — it is a fermentation vessel, a clean bench and some training. It was legal risk, and the law took most of it away.

That is why inoculants are modelled at 4.2 per cent

The Global Agricultural Biologicals market grows from USD 13.45 billion in 2025 to USD 27.50 billion in 2033 at 9.35 per cent, on volume of 1.085 to 1.76 million tonnes. Inoculants are modelled at 4.2 per cent — less than half the market rate and the slowest of the three families.

That is not a view about demand. Brazilian soybean growers will use rhizobia in 2033 on more hectares than in 2025, and on roughly 90 per cent of the Mato Grosso soybean area they already do. It is a view about who supplies it. A category with R$ 10.4 per hectare of revenue intensity has the thinnest possible cushion against a substitute a grower can make himself.

The implementing regulation is the largest single variable in this forecast

Nobody yet knows how the regulation will be written, and the three open questions are worth naming because the answers move this market by billions.

First, scope. Is on-farm production confined to a grower’s own use, or opened to contracting — a mill, a co-operative or a service provider multiplying for members? Contracted multiplication is the same economics as a commercial product with none of the product’s overheads, and it would compress inoculant pricing faster than own-use ever could.

Second, quality obligation. Does an on-farm product carry any viable-cell count, contamination limit or labelling requirement? A statute with a quality floor raises the cost of the substitute and narrows the discount to a bought product. One without it makes price the only variable.

Third, who certifies. A self-declaration regime and an inspected regime are different markets.

Every one of those decisions sits in secondary legislation rather than in Lei 15.070 itself. That is the single largest unhedged assumption in an eight-year forecast, and it is why inoculants carry the most conservative rate in the report.

What the market does instead

If the widest-adopted product cannot carry value, growth has to come from biocontrol — where performance must be re-proven every season. In 2025 biofungicides grew 41 per cent in value and bionematicides added roughly 16 million hectares, about 60 per cent, the fastest area expansion of any segment.

That is the trade the statute creates. The category that made biologicals normal in Brazil is now the category with the smallest prize and the cheapest imitator. The category with the hardest agronomy is the one that has to carry an 9.35 per cent forecast.

The full dataset, segmentation and eight-year value path are in the Global Agricultural Biologicals Market report.